The use of sodium hyaluronate (Healon) in the treatment of complicated cases of retinal detachment

Abstract

Thirty-six eyes with retinal detachment and various degrees of proliferative vitreoretinopathy were operated with conventional buckling techniques and the additional use of intravitreal injected sodium hyaluronate (Healon). Eighteen eyes (50%) had re-attached retina 6 months post-operatively. The re-attachment rate depended upon the severity of the proliferative vitreoretinopathy. Three of 4 eyes with grade B, 4 of 5 with grade C-1, 8 of 13 with grade C-2, 2 of 11 with grade C-3 and 1 of 3 eyes with grade D-1 were reattached. Major complication occurred in 3 aphakic eyes where persistent intraocular pressure rise to 60-70 mmHg necessitated removal of Healon to normalize the intraocular pressure. In one eye Healon passed through a retinal rupture to the subretinal space.

Postoperative course of intraocular pressure after cataract surgery with combined primary posterior capsulorhexis and posterior optic buttonholing

“…For much larger volumes of OVD, IOP rises have been observed only after OVD injection into the posterior segment for retinal detachment surgery. 13 Intraocular pressure-lowering medication may be applied once at the end of cataract surgery to lower IOP in the first postoperative hours. 12 The same fixed dorzolamide-timolol combination used in the present study has been shown to be effective in reducing IOP 6 hours and 20 to 24 hours after cataract surgery.…”

A new model for in vitro testing of vitreous substitute candidates

“…The use of derivates of sodium hyaluronic acid in vitreoretinal surgery predates their ubiquitous use in cataract and anterior segment surgery [12,14,[40][41][42], but their use in a clinical setting has been limited mainly due to concern about short term side effects and retention time [41,43]. Healaflow® is a commercially available compound consisting of a cross-linked sodium hyaluronic acid hydrogel and is FDA approved for use in glaucoma surgery [22,23].…”